Johnson & Johnson: Why I See Downside Ahead [Seeking Alpha]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Seeking Alpha
So JNJ expects its operational sales to be between $99.7 billion and $100.7 billion, up from $99.5 billion to $100.5 billion. In my view, this is due to the sharp decline in demand for Stelara, JNJ's former "cash cow" in the immunology franchise. Moreover, JNJ's acquisition of Intra-Cellular Therapies for $14.6 billion doesn't meet my expectations, as Caplyta sales grew by only 8.4% quarter-on-quarter to $270 million. Further in this article, you'll learn about additional reasons why I believe Johnson &Johnson's risk/reward profile is still unattractive. Margaryta Basarab/iStock via Getty Images So, since my last article Johnson & Johnson: Strong Run May Be Ending, " which, by the way, caused an extremely negative reaction from you, Johnson & Johnson ( JNJ ) aka J&J This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of LEGN either through stock ownership, options, or other derivatives. I wrote this article myself, and it
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- U.S. judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims [BNN Bloomberg (Canada)]BNN Bloomberg
- CFOs On the Move: Week ending April 17 [Yahoo! Finance]Yahoo! Finance
- U.S. judge rejects Bayer's bid to block Johnson & Johnson prostate cancer drug claims [Yahoo! Finance]Yahoo! Finance
- Barclays Raises Johnson & Johnson (JNJ) Price Target on Strong Pharma Momentum [Yahoo! Finance]Yahoo! Finance
- Citadel's chief people officer leaves the firm as hedge funds battle for talent [Business Insider]Business Insider
JNJ
Earnings
- 4/14/26 - Beat
JNJ
Sec Filings
- 4/14/26 - Form 8-K
- 3/26/26 - Form SCHEDULE
- 3/18/26 - Form 13F-HR/A
- JNJ's page on the SEC website